Albert Attia, MD
Radiation Oncology · Jacksonville, FLNPI 1205008349
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,500 of the $2,391 with a category attached, or 62.7%. Novocure Inc. accounts for 68.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $1,575 and has fallen 82.5% since, to $275 in 2025.
Across 17 payments — averaging $140.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$2K
- Boston Scientific$162
- Elekta, Inc.$151
- Ferring Pharmaceuticals Inc.$135
- Olympus America Inc.$134
- Calyxo, Inc.$124
- plus $53 from 3 others
Across 5 payments — averaging $2963.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure Inc.$15K
What the payments were for
- Consulting fees$1,50063%
- Food & beverage$89137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 7 | $1,632 |
| Boston Scientific | 2 | $162 |
| Elekta, Inc. | 1 | $151 |
| Ferring Pharmaceuticals Inc. | 1 | $135 |
| Olympus America Inc. | 2 | $134 |
| Calyxo, Inc. | 1 | $124 |
| Reflexion Medical, Inc. | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$1,500
- SpaceOAR System$148
- ADSTILADRIN$135
- CVAC Aspiration System$124
How this compares
$2,391 in reported general payments places this provider in the 70th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 33 | $82,737 |
| Tamsulosin Hcl | 127 | $2,471 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Jacksonville
- Daniel TrifilettiJacksonville$24K
- Bradford HoppeJacksonville$11K
- Scot AckermanJacksonville$8K
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.